(2018). Serum potassium as a predictor of adverse clinical outcomes in patients with chronic kidney disease: new risk equations using the UK clinical practice research datalink. BMC Nephrol. http://doi.org/10.1186/s12882-018-1007-1.
(2019). Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom. J Am Heart Assoc. http://doi.org/10.1161/jaha.119.012655.
(2019). Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21 334 patients in the UK. ESC Heart Fail. http://doi.org/10.1002/ehf2.12402.
(2019). Epidemiology and health outcomes associated with hyperkalemia in a primary care setting in England. BMC Nephrol. http://doi.org/10.1186/s12882-019-1250-0.
(2020). Risk factors associated with the incidence and recurrence of hyperkalaemia in patients with cardiorenal conditions. Int J Clin Pract. http://doi.org/10.1111/ijcp.13941.